Related references
Note: Only part of the references are listed.Can Chronic Pain Patients Be Adequately Treated Using Generic Pain Medications to the Exclusion of Brand-Name Ones?
Kenneth D. Candido et al.
AMERICAN JOURNAL OF THERAPEUTICS (2016)
Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain
E. Niclas Jonsson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Pharmacologic Therapies in Musculoskeletal Conditions
Melinda S. Loveless et al.
MEDICAL CLINICS OF NORTH AMERICA (2016)
The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain
L. Xu et al.
OSTEOARTHRITIS AND CARTILAGE (2016)
When Is Osteonecrosis Not Osteonecrosis? Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program
Marc C. Hochberg et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Emerging Targets for the Management of Osteoarthritis Pain
Anne-Marie Malfait et al.
CURRENT OSTEOPOROSIS REPORTS (2016)
Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies
M. C. Hochberg
OSTEOARTHRITIS AND CARTILAGE (2015)
Movement Evoked Pain and Mechanical Hyperalgesia after Intramuscular Injection of Nerve Growth Factor: A Model of Sustained Elbow Pain
Michael Joseph Gerard Bergin et al.
PAIN MEDICINE (2015)
Exploring the Role of Tanezumab as a Novel Treatment for the Relief of Neuropathic Pain
Candace Bramson et al.
PAIN MEDICINE (2015)
Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain
Thomas J. Schnitzer et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial
Andra Rodica Balanescu et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and Safety of Intravenous Tanezumab for the Symptomatic Treatment of Osteoarthritis: 2 Randomized Controlled Trials versus Naproxen
Evan F. Ekman et al.
JOURNAL OF RHEUMATOLOGY (2014)
OARSI guidelines for the non-surgical management of knee osteoarthritis
T. E. McAlindon et al.
OSTEOARTHRITIS AND CARTILAGE (2014)
Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain
Joseph S. Gimbel et al.
PAIN (2014)
Brief Report: AntiCarbamylated Protein Antibodies Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis
Jing Shi et al.
ARTHRITIS AND RHEUMATISM (2013)
Tanezumab Reduces Osteoarthritic Hip Pain Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Mark T. Brown et al.
ARTHRITIS AND RHEUMATISM (2013)
A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee
Egilius L. H. Spierings et al.
PAIN (2013)
Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain
Alan J. Kivitz et al.
PAIN (2013)
Tanezumab Reduces Osteoarthritic Knee Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Mark T. Brown et al.
JOURNAL OF PAIN (2012)
Increased cutaneous NGF and CGRP-labelled trkA-positive intra-epidermal nerve fibres in rat diabetic skin
Laura Evans et al.
NEUROSCIENCE LETTERS (2012)
TANEZUMAB THERAPY FOR CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME (CP/CPPS): PRELIMINARY ASSESSMENT OF EFFICACY AND SAFETY IN A RANDOMIZED CONTROLLED TRIAL
J. Curtis Nickel et al.
JOURNAL OF UROLOGY (2011)
Proof of Concept Trial of Tanezumab for the Treatment of Symptoms Associated With Interstitial Cystitis
R. J. Evans et al.
JOURNAL OF UROLOGY (2011)
Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study
H. Nagashima et al.
OSTEOARTHRITIS AND CARTILAGE (2011)
Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain
T. J. Schnitzer et al.
OSTEOARTHRITIS AND CARTILAGE (2011)
Efficacy and safety of tanezumab in the treatment of chronic low back pain
Nathaniel Katz et al.
PAIN (2011)
A multiple-dose toxicity study of tanezumab in cynomolgus monkeys
Mark Zorbas et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2011)
Nerve Growth Factor as a Signaling Molecule for Nerve Cells and also for the Neuroendocrine-Immune Systems
Marco Fiore et al.
REVIEWS IN THE NEUROSCIENCES (2011)
Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee
Nancy E. Lane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
NGF and Its Receptor System A New Dimension in the Pathogenesis of Psoriasis and Psoriatic Arthritis
Smriti K. Raychaudhuri et al.
CONTEMPORARY CHALLENGES IN AUTOIMMUNITY (2009)
Structure of Posttraumatic Stress Disorder Symptoms in Pain and Pain-Free Patients Scheduled for Major Surgery
Gabrielle M. Page et al.
JOURNAL OF PAIN (2009)
Nerve growth factor gene delivery: Animal models to clinical trials
Mark H. Tuszynski
DEVELOPMENTAL NEUROBIOLOGY (2007)
Phosphoinositide-3-kinase and mitogen activated protein kinase signaling pathways mediate acute NGF sensitization of TRPV1
Weiguo Zhu et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2007)
Novel class of pain drugs based on antagonism of NGF
FF Hefti et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2006)
NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels
XM Zhang et al.
EMBO JOURNAL (2005)
Is there an association between the use of different types of nonsteroidal antiinflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam study
M Reijman et al.
ARTHRITIS AND RHEUMATISM (2005)
Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization
MA Sevcik et al.
PAIN (2005)
Signalling pathways involved in the sensitisation of mouse nociceptive neurones by nerve growth factor
JK Bonnington et al.
JOURNAL OF PHYSIOLOGY-LONDON (2003)
Individual and combined effects of TrkA and p75NTR nerve growth factor receptors -: A role for the high affinity receptor site
SP Lad et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Injection of nerve growth factor into human masseter muscle evokes longlasting mechanical allodynia and hyperalgesia
P Svensson et al.
PAIN (2003)
A role for the TTX-resistant sodium channel Nav 1.8 in NGF-induced hyperalgesia, but not neuropathic pain
BJ Kerr et al.
NEUROREPORT (2001)
Knee pain and joint loading in subjects with osteoarthritis of the knee
DE Hurwitz et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2000)
Share Paper
